Gemcitabine or Gemcitabine Plus Docetaxel After Cisplatin, Etoposide and Radiation in Non Small Cell Lung Cancer (NSCLC)
Status:
Completed
Trial end date:
2009-02-01
Target enrollment:
Participant gender:
Summary
To assess the 2 year survival of patients with Stage III unresectable non-small cell lung
cancer receiving consolidation gemcitabine or gemcitabine plus docetaxel following concurrent
chemotherapy and radiation.